Department of Intensive Care, Raymond Poincaré Hospital, GHU APHP Université Paris Saclay, Garches, France.
Laboratory Inflammation & Infection, U1173, School of Medicine Simone Veil, Université Paris Saclay-UVSQ and - INSERM 2 Avenue De La Source De La Bièvre, Montigny-le-Bretonneux, France.
Expert Rev Anti Infect Ther. 2021 May;19(5):635-647. doi: 10.1080/14787210.2021.1846522. Epub 2020 Nov 23.
: Sepsis, a dysregulated host response to infection, is a major cause of morbidity and mortality worldwide. Early identification and evidence-based treatment of sepsis are associated with improved outcomes.: This narrative review was undertaken following a PubMed search for English language reports published before July 2020 using the terms 'sepsis,' 'septic shock,' 'fluids,' 'fluid therapy,' 'albumin,' 'corticosteroids,' 'vasopressor.' Emerging management strategies were identified following a search of the ClinicalTrails.gov database using the term 'sepsis.' Additional reports were identified by examining the reference lists of selected articles and based on personnel knowledge of the field of sepsis.: The core treatment of sepsis relies on source control, early antibiotics, and organ support. The main emerging strategies focus on immunomodulation, artificial intelligence, and on multi-omics approaches for a personalized therapy.
: 脓毒症是一种宿主对感染的失调反应,是全球发病率和死亡率的主要原因。脓毒症的早期识别和基于证据的治疗与改善预后相关。: 本综述是在 PubMed 上进行的一项英语文献检索的基础上进行的,检索时间为 2020 年 7 月之前,使用的术语有“脓毒症”、“感染性休克”、“液体”、“液体疗法”、“白蛋白”、“皮质类固醇”、“血管加压素”。通过在 ClinicalTrails.gov 数据库中使用“脓毒症”一词搜索,确定了新出现的治疗策略。通过检查选定文章的参考文献列表,并根据脓毒症领域人员的知识,确定了其他报告。: 脓毒症的核心治疗依赖于源头控制、早期使用抗生素和器官支持。主要的新兴策略集中在免疫调节、人工智能和多组学方法的个性化治疗上。